» Articles » PMID: 34108552

Prognostic Significance of Bone Marrow and Spleen F-FDG Uptake in Patients with Colorectal Cancer

Overview
Journal Sci Rep
Specialty Science
Date 2021 Jun 10
PMID 34108552
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Serum inflammatory markers are used in the prognostication of colorectal cancer (CRC); however, the corresponding role of positron emission tomography (PET)-derived inflammatory markers remains unclear. This study aimed to investigate the prognostic value of F-fluorodeoxyglucose (FDG) uptake in the bone marrow and spleen of patients with CRC and evaluate the relationship between FDG uptake estimates in these organs and serum inflammatory markers. In total, 411 patients who underwent preoperative FDG PET/computed tomography (CT) within 1 month of surgery were enrolled. The mean standardized uptake values of the bone marrow and spleen were normalized to the value of the liver, thereby generating bone marrow-to-liver uptake ratio (BLR) and spleen-to-liver uptake ratio (SLR) estimates. The value of BLR and SLR in predicting overall survival (OS) was assessed using the Cox proportional hazards model. The correlation between BLR or SLR and neutrophil-to-lymphocyte ratio (NLR) was evaluated. The predictive accuracy of BLR alone and in combination with SLR was compared using the integrated area under the receiver operating characteristic curves (iAUC). In the univariate analysis, BLR (> 1.06) and SLR (> 0.93) were significant predictors of OS. In the multivariate analysis, BLR was an independent predictor of OS (hazard ratio = 5.279; p < 0.001). Both BLR and SLR were correlated with NLR (p < 0.001). A combination of BLR and SLR was better than BLR alone at CRC prognostication (iAUC, 0.561 vs. 0.542). FDG uptake estimates in the bone marrow and spleen may be useful imaging-derived biomarkers of systemic inflammation, supporting CRC prognostication.

Citing Articles

Predictive value of longitudinal systemic inflammatory markers for pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer.

Tao X, Zhang Q, Yuan P, Wang S, Ying J, Li N Transl Lung Cancer Res. 2024; 13(11):2972-2986.

PMID: 39670003 PMC: 11632438. DOI: 10.21037/tlcr-24-598.


Healthy tissue metabolism assessed by [F]FDG PET/CT as a marker of prognosis and adverse events in advanced Hodgkin lymphoma patients.

Malaih A, Kirkwood A, Johnson P, Radhakrishnan V, Fischer B, Barrington S Sci Rep. 2024; 14(1):12613.

PMID: 38824206 PMC: 11144227. DOI: 10.1038/s41598-024-63349-5.


Relationship of FDG PET/CT imaging features with tumor immune microenvironment and prognosis in colorectal cancer: a retrospective study.

Lee J, Ahn H, Yoo I, Hong S, Baek M, Kang D Cancer Imaging. 2024; 24(1):53.

PMID: 38627864 PMC: 11020988. DOI: 10.1186/s40644-024-00698-4.


Preoperative F-FDG PET/CT in Patients with Presumed Localized Colon Cancer: A Prospective Study with Long-Term Follow-Up.

Aymard S, Rust E, Kaseb A, Liu D, Hubele F, Romain B Cancers (Basel). 2024; 16(1).

PMID: 38201660 PMC: 10777901. DOI: 10.3390/cancers16010233.


Prognostic Value of Serum Neutrophil to Lymphocyte Ratio and SUVmax in Stage I and II Colon Cancer.

Choi S, Park J, Baik H, An M, Bae K, Lee S Asian Pac J Cancer Prev. 2023; 24(11):3837-3844.

PMID: 38019241 PMC: 10772752. DOI: 10.31557/APJCP.2023.24.11.3837.


References
1.
Lee J, Baek M, Ahn T, Lee S . Fluorine-18-fluorodeoxyglucose uptake of bone marrow on PET/CT can predict prognosis in patients with colorectal cancer after curative surgical resection. Eur J Gastroenterol Hepatol. 2017; 30(2):187-194. DOI: 10.1097/MEG.0000000000001018. View

2.
Son W, Shin S, Park S, Lee S, Park E, Baik S . Clinical Impact of Combined Modified Glasgow Prognostic Score and C-Reactive Protein/Albumin Ratio in Patients with Colorectal Cancer. Diagnostics (Basel). 2020; 10(11). PMC: 7690417. DOI: 10.3390/diagnostics10110859. View

3.
Van de Wiele C, VandeVyver F, Debruyne C, Philippe J, van Meerbeeck J . FDG uptake by the bone marrow in NSCLC patients is related to TGF-beta but not to VEGF or G-CSF serum levels. Eur J Nucl Med Mol Imaging. 2007; 35(3):519-22. DOI: 10.1007/s00259-007-0628-6. View

4.
Inoue K, Goto R, Okada K, Kinomura S, Fukuda H . A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity. Ann Nucl Med. 2009; 23(7):643-9. DOI: 10.1007/s12149-009-0286-9. View

5.
Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View